EYEN vs. VYNE, ACXP, MRKR, BCTX, NXTC, PMN, IPA, APLM, XLO, and UNCY
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include VYNE Therapeutics (VYNE), Acurx Pharmaceuticals (ACXP), Marker Therapeutics (MRKR), BriaCell Therapeutics (BCTX), NextCure (NXTC), ProMIS Neurosciences (PMN), ImmunoPrecise Antibodies (IPA), Apollomics (APLM), Xilio Therapeutics (XLO), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Eyenovia received 145 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 65.00% of users gave Eyenovia an outperform vote while only 58.54% of users gave VYNE Therapeutics an outperform vote.
Eyenovia presently has a consensus price target of $10.00, indicating a potential upside of 1,056.07%. VYNE Therapeutics has a consensus price target of $7.38, indicating a potential upside of 171.14%. Given Eyenovia's higher possible upside, equities analysts clearly believe Eyenovia is more favorable than VYNE Therapeutics.
In the previous week, VYNE Therapeutics had 5 more articles in the media than Eyenovia. MarketBeat recorded 7 mentions for VYNE Therapeutics and 2 mentions for Eyenovia. VYNE Therapeutics' average media sentiment score of 0.47 beat Eyenovia's score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.
Eyenovia has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,710.38%. VYNE Therapeutics' return on equity of -77.46% beat Eyenovia's return on equity.
Eyenovia has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
25.8% of Eyenovia shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 7.8% of Eyenovia shares are held by insiders. Comparatively, 1.8% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Eyenovia has higher earnings, but lower revenue than VYNE Therapeutics. Eyenovia is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Eyenovia beats VYNE Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
